Navigation Links
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
Date:10/31/2007

SYMBOL - BCL.P

VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ - Beanstalk Capital Ltd. ( the "Company") is pleased to announce that further to the Company's press release dated October 16, 2007, in which the Company and iCo Therapeutics Inc. ("iCo") announced that they had entered into an arm's length arrangement agreement dated October 15, 2007 (the "Arrangement Agreement"), the Company and iCo would now like to announce that they have entered into an amended and restated Arrangement Agreement dated October 25, 2007. Under the amended and restated Arrangement Agreement the brokered equity financing for the proposed transaction will now be conducted through iCo, rather than the Company. Canaccord Capital Corporation will act as the lead agent for the private placement and Haywood Securities Inc. will participate as a syndicate member. The brokered financing will consist of the sale of 1,840,000 subscription receipts of iCo at $0.98 per subscription receipt to raise gross proceeds of $1,803,200. Canaccord will have the option to increase the size of the offering by selling up to an additional 1,020,000 subscription receipts for additional gross proceeds of $999,600. The proceeds from the sale of the subscription receipts will be held in escrow by a third party pending closing of the qualifying transaction ("QT"). As a result of now raising funds in iCo and completing the QT under a plan of arrangement, the shares issued upon exercise of the subscription receipts subscribed for in this financing will be free trading upon closing of the QT.

Significant Conditions to Closing of QT

Completion of the transaction is subject to a number of conditions including, without limitation, approval by iCo's shareholders, approval of the Supreme Court of British Columbia and the TSX Venture Exchange, and completion by iCo of a private placement of subscription receipts having a minimum aggregate subscription price of $1,803,200. There c
'/>"/>

SOURCE Beanstalk Capital Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Breaking down Wisconsins angel capital numbers
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Visions: Broderick says Wisconsin should be in top third in venture capital
4. In pursuit of capital, be sure to track your private offering
5. Wisconsin building toward the major leagues of venture capital
6. Research explains why women lack equal access to angel capital
7. When raising capital, why use a Private Placement Memorandum?
8. Capital-raising term sheets for angels and venture capitalists
9. Early Stage, Step 9: Raising capital in the securities landscape
10. Translating the language of capital-raising
11. Visions: Carbone bullish on Wisconsin venture capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... they,ve been miniaturized to take up less space and ... data conversion electronics on the James Webb Space Telescope ... convert analog signals to digital signals and provide better ... "SIDECAR" have been miniaturized from a volume of about ...
... Feb. 20 Kensey Nash Corporation,(Nasdaq: KNSY ... clearance for an,important vessel wall detection technology from ... the guidance provided by the,Safe-Cross(R) RF CTO System. ... radio frequency (RF) energy to safely,cross and recanalize ...
... Calif., Feb. 20 5AM Ventures, specializing,in seed ... announced the expansion of the firm,s investment team ... Partner. 5AM Ventures,also announced the promotion of two ... and R. Andrew McMillan, PhD, to Principal. Drs. ...
Cached Biology Technology:Amazing minaturized 'SIDECAR' drives Webb telescope's signal 2Amazing minaturized 'SIDECAR' drives Webb telescope's signal 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 2Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 3Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 4Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology 55AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 25AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a leading ... illness in very young and elderly populations. Despite ... host cells through the fusion protein RSV F, ... peptides that prevent bundle formation limit RSV infection ... to degradation. In this issue of the ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... University of North Carolina at Chapel Hill have purified a ... by reversing a molecular modification previously thought permanent. , In ... is able to remove a methyl group from histone H3, ... just last year, the addition of a methyl group to ...
... Hospital of Philadelphia leads a multi-center $6.7 million program ... Mental Health (NIMH) to explore a novel approach to ... and clinical trials in adult patients, the new grant ... immunodeficiency virus: sites on immune cells known as neurokinin-1 ...
... the work of machines that contain dozens of molecules, chiefly ... now have a nearly complete "parts list" of such machines; ... pieces go. A new study by scientists at the European ... some of the smallest and trickiest components in the cellular ...
Cached Biology News:Novel enzyme offers new look at gene regulation 2Federal grant funds research on novel HIV therapy 2Federal grant funds research on novel HIV therapy 3Many needles, many haystacks 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... cytopathic effect inhibition assays, also known as ... assay measures the antibody's ability to neutralize ... types include; tissue culture supernatents; serum and ... unit is defined as the quantity of ...
... Yeast nitrogen base (YNB) is a base ... yeast media. YNB contains ammonium sulfate but does ... single-use pouches are available. Each pouch contains ... for Pichia media or 1000 ml of 10X ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
Biology Products: